Acelyrin, Inc. SLRN
We take great care to ensure that the data presented and summarized in this overview for ACELYRIN, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SLRN
Top Purchases
Top Sells
About SLRN
Insider Transactions at SLRN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 21
2025
|
Ayur Maya Capital Management Company, LP Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
9,334,735
-100.0%
|
-
|
|
May 21
2025
|
Amar Murugan Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
121,587
-100.0%
|
-
|
|
May 21
2025
|
Mina Kim Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
770,833
-100.0%
|
-
|
|
May 21
2025
|
Mina Kim Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
89,526
+10.41%
|
-
|
|
May 21
2025
|
Daniel J. Becker Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,999
-100.0%
|
-
|
|
May 21
2025
|
Dawn Svoronos Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
May 21
2025
|
Patrick Machado Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
14,675
-100.0%
|
-
|
|
May 21
2025
|
Henry O Gosebruch Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
50,000
-100.0%
|
-
|
|
May 21
2025
|
Shephard Mpofu Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
121,789
-100.0%
|
-
|
|
May 21
2025
|
Beth C Seidenberg Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
9,790,729
-100.0%
|
-
|
|
May 21
2025
|
Beth C Seidenberg Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
60,000
-100.0%
|
-
|
|
May 15
2025
|
Mina Kim Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
21,297
-1.53%
|
$42,594
$2.17 P/Share
|
|
May 15
2025
|
Mina Kim Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,851
+4.21%
|
-
|
|
Mar 17
2025
|
Mina Kim Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
17,986
-2.61%
|
$35,972
$2.74 P/Share
|
|
Mar 17
2025
|
Amar Murugan Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,913
-3.12%
|
$7,826
$2.74 P/Share
|
|
Mar 17
2025
|
Shephard Mpofu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,211
-2.57%
|
$6,422
$2.74 P/Share
|
|
Jan 23
2025
|
Shephard Mpofu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+50.0%
|
-
|
|
Jan 23
2025
|
Mina Kim Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
575,000
+45.46%
|
-
|
|
Jan 23
2025
|
Amar Murugan Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+49.9%
|
-
|
|
Jul 17
2024
|
Daniel J. Becker Director |
SELL
Open market or private sale
|
Direct |
1
-0.03%
|
$6
$6.86 P/Share
|
Last 12 Months Summary
Buy / Acquisition
945K
Shares
From
3
Insiders
| Grant, award, or other acquisition | 945K shares |
|---|
Sell / Disposition
20.3M
Shares
From
14
Insiders
| Sale (or disposition) back to the issuer | 20.3M shares |
|---|---|
| Payment of exercise price or tax liability | 21.3K shares |
| Open market or private sale | 25.1K shares |